science
plus
.abes.fr
|
explorer
À propos de :
Curigliano Giuseppe
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
foaf:Person
, within Data Space :
scienceplus.abes.fr
associated with source
document(s)
Type:
Person
New Facet based on Instances of this Class
Attributs
Valeurs
type
Person
name
Curigliano Giuseppe
Curigliano G.
Curigliano G
personal mailbox
giuseppe.curigliano@ieo.it
familyName
Curigliano
Given name
G
G.
Giuseppe
is
relates
of
http://hub.abes.fr/oup/periodical/annonc/2003/volume_14/issue_5/101093annoncmdg218/authorship/5
http://hub.abes.fr/oup/periodical/annonc/2006/volume_17/issue_7/101093annoncmdj126/authorship/1
http://hub.abes.fr/oup/periodical/annonc/2009/volume_20/issue_3/101093annoncmdn650/authorship/3
http://hub.abes.fr/oup/periodical/annonc/2001/volume_12/issue_11/101023a1013163831194/authorship/2
http://hub.abes.fr/oup/periodical/jnci/2007/volume_99/issue_17/101093jncidjm092/authorship/3
http://hub.abes.fr/oup/periodical/annonc/2000/volume_11/issue_8/101023a1008334404825/authorship/10
http://hub.abes.fr/oup/periodical/annonc/2002/volume_13/issue_1/101093annoncmdf004/authorship/2
http://hub.abes.fr/oup/periodical/annonc/2005/volume_17/issue_5/101093annoncmdj083/authorship/1
http://hub.abes.fr/oup/periodical/jnci/2005/volume_97/issue_6/101093jncidji076/authorship/5
http://hub.abes.fr/oup/periodical/annonc/2003/volume_14/issue_10/101093annoncmdg411/authorship/2
http://hub.abes.fr/oup/periodical/annonc/2002/volume_13/issue_6/101093annoncmdf166/authorship/1
http://hub.abes.fr/oup/periodical/annonc/2001/volume_12/issue_11/101023a1013133415945/authorship/5
http://hub.abes.fr/oup/periodical/annonc/2000/volume_11/issue_7/101023a1008319923516/authorship/6
http://hub.abes.fr/oup/periodical/annonc/2006/volume_17/issue_10/101093annoncmdl088/authorship/1
http://hub.abes.fr/oup/periodical/annonc/2000/volume_11/issue_1/101023a1008364801718/authorship/6
http://hub.abes.fr/oup/periodical/annonc/2005/volume_16/issue_4/101093annoncmdi101/authorship/7
http://hub.abes.fr/oup/periodical/annonc/2004/volume_15/issue_12/101093annoncmdh482/authorship/9
http://hub.abes.fr/oup/periodical/annonc/2005/volume_16/issue_7/101093annoncmdi213/authorship/4
http://hub.abes.fr/oup/periodical/carcin/1996/volume_17/issue_5/101093carcin175911/authorship/1
http://hub.abes.fr/oup/periodical/carcin/1998/volume_19/issue_2/101093carcin192353/authorship/3
http://hub.abes.fr/oup/periodical/annonc/2004/volume_15/issue_4/101093annoncmdh146/authorship/2
http://hub.abes.fr/oup/periodical/jnci/2007/volume_99/issue_15/101093jncidjm051/authorship/5
http://hub.abes.fr/oup/periodical/annonc/2001/volume_12/issue_5/101023a1011173806900/authorship/1
is
Author
of
Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase
4-Aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study.
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer
Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors
Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial
CDX-2 should be included in the work-up of patients with lung metastases from unknown primary
Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?
Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas
Re: Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer
Bone scan had no role in the staging of 765 consecutive operable T1-2N0-1 breast cancer patients without skeletal symptoms
Breast cancer vaccines: a clinical reality or fairy tale?
Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer
Reply to Letter to the Editor: ‘Toxic epidermal necrolysis in patients with malignancies’, by G. Gravante, G. Esposito, M. Marianetti, D. Delogu, G. Sconocchia & A. Montone (doi:10.1093/annonc/mdl089)
Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer
Gemcitabine-induced systemic capillary leak syndrome
Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay
Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter
Reply to the article “Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity” by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550): … and in humans?
Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype
Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma
Alternative Linked Data Documents:
ODE
Content Formats:
RDF
ODATA
Microdata
